Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Nerve Block of the Vastus Medialis and Anterior Obturator Branch in Anterior Cruciate Ligament Reconstruction With DIDT Graft (RECUP-NVM)

6 de novembro de 2026 atualizado por: GCS Ramsay Santé pour l'Enseignement et la Recherche

The goal of this randomized clinical trial is to evaluate whether a targeted regional anesthesia strategy combining an adductor canal block, a nerve to the vastus medialis (NVM) block, an anterior obturator nerve branch block, and an iPACK block improves postoperative recovery in patients undergoing anterior cruciate ligament (ACL) reconstruction using a hamstring tendon (semitendinosus and gracilis; DIDT) graft, compared with the standard analgesic protocol used in participating centres, consisting of a femoral nerve block combined with an iPACK block.

The main question the study aims to answer is whether this targeted combination of nerve blocks, compared with the standard femoral nerve block plus iPACK regimen, improves the quality of postoperative recovery, as measured by the Quality of Recovery-15 (QoR-15) score at 24 hours after surgery.

The study hypothesis is that the targeted adductor canal + NVM + anterior obturator branch + iPACK strategy will significantly improve postoperative recovery quality at 24 hours compared with the standard femoral nerve block + iPACK protocol, with an expected improvement of at least 8 points on the QoR-15 score. This 8-point difference represents the minimal clinically important difference (MCID) for this questionnaire (Léger et al., 2020). The QoR-15 is a validated global recovery assessment tool, available in French, and sensitive to variations in recovery quality in outpatient orthopedic surgery (Nakase et al., 2021). An improvement of at least 8 points at 24 hours would therefore indicate a clinically meaningful benefit from the patient's perspective.

The study will also assess:

  • Postoperative pain at rest and during mobilization.
  • Opioid consumption during the first 48 hours after surgery.
  • Incidence of postoperative nausea and vomiting.
  • Time to first ambulation.
  • Postoperative thigh edema.
  • Neuromuscular recovery of the thigh.
  • Patient satisfaction with analgesic management.
  • Adverse events related to regional anesthesia.

Participants will be randomly assigned to one of two treatment groups. All participants will undergo ACL reconstruction with a DIDT graft. Participants in the comparator group will receive a femoral nerve block combined with an iPACK block. Participants in the intervention group will receive a targeted regional anesthesia strategy combining an adductor canal block, a nerve to the vastus medialis (NVM) block, an anterior branch of the obturator nerve block, and an iPACK block.

The planned volumes and doses for each block in the two randomized strategies are detailed as follows: Compared with the control group, which receives a femoral nerve block with 15 mL and an iPACK block with 20 mL of ropivacaine 0.35% (total volume: 35 mL; total dose: 122.5 mg), the intervention group receives an adductor canal block with 10 mL, a nerve to the vastus medialis block with 5 mL, an anterior branch of the obturator nerve block with 6 mL, and an iPACK block with 20 mL of ropivacaine 0.35% (total volume: 41 mL; total dose: 143.5 mg). Thus, the intervention group involves two additional nerve block targets and an additional 6 mL of ropivacaine, corresponding to an additional dose of 21 mg (+17.1%) compared with the control group. The cumulative dose will be checked against the patient-specific safety limits before performing the blocks. Patients in whom the blocks cannot be safely performed within these limits will not be included.

Postoperative assessments will include pain scores, QoR-15 questionnaires, opioid consumption, nausea and vomiting, thigh measurements, and neuromuscular function assessments during the first 48 hours after surgery. Patient satisfaction and safety outcomes will also be assessed during follow-up.

The primary outcome will compare the QoR-15 score at 24 hours between the two groups, with an 8-point difference considered clinically meaningful.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

108

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 60 anos (Adulto)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Adult patients aged 18 to 60 years.
  • Patients with a primary anterior cruciate ligament (ACL) injury.
  • Patients scheduled for ACL reconstruction using a DIDT graft under general anesthesia.
  • Patients managed as ambulatory surgery or short stay.
  • Patients who understand the validated French version of the QoR-15 questionnaire.
  • Patients who have given written informed consent to participate in the study.
  • Patients affiliated with or beneficiaries of a social security system.

Exclusion Criteria:

  • Patients with a body weight below 50 kg, as the planned cumulative ropivacaine dose could exceed the safety limit of 3 mg/kg.
  • Patients with allergy to local anesthetics or a contraindication to peripheral nerve blocks.
  • Patients with lower-limb neuropathy.
  • Patients with coagulation disorders or on major anticoagulation.
  • Patients with chronic pain requiring more than 30 mg morphine-equivalents per day.
  • Patients undergoing revision ACL reconstruction or a major combined surgical procedure.
  • Pregnant women.
  • Patients unable to complete the questionnaires or who refuse to participate.
  • Pregnant women or women who may be pregnant (of childbearing potential without effective contraception) or who are breastfeeding.
  • Protected adults: patients under guardianship, curatorship or other legal protection, deprived of liberty, or unable to provide informed consent.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Adductor Canal + iPACK + NVM and Anterior Obturator Nerve Blocks

Participants will undergo anterior cruciate ligament reconstruction using a semitendinosus and gracilis (DIDT) graft. They will receive a targeted regional anesthesia protocol consisting of an adductor canal block, a nerve to the vastus medialis (NVM) block, an iPACK block, and a block of the anterior branch of the obturator nerve.

Ultrasound-guided infiltration between the popliteal artery and the posterior capsule of the knee (iPACK) administered as part of the regional anesthesia protocol.

Ultrasound-guided nerve block targeting the nerve to the vastus medialis (NVM), administered in addition to theadductor canal and iPACK blocks in the experimental arm.

Ultrasound-guided block of the anterior branch of the obturator nerve, administered in addition to the adductor canal and iPACK blocks in the experimental arm.

Ultrasound-guided adductor canal block administered as part of the targeted regional anesthesia protocol for ACL reconstruction in the experimental arm.

Comparador Ativo: Femoral + iPACK Nerve Blocks

Participants will undergo anterior cruciate ligament reconstruction using a semitendinosus and gracilis (DIDT) graft. They will receive the standard regional anesthesia protocol consisting of a femoral nerve block and an iPACK block, without additional nerve blocks of the nerve to the vastus medialis (NVM) or anterior branch of the obturator nerve.

Ultrasound-guided infiltration between the popliteal artery and the posterior capsule of the knee (iPACK) administered as part of the regional anesthesia protocol.

Ultrasound-guided femoral nerve block administered as part of the standard regional anesthesia protocol for ACL reconstruction.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Quality of Recovery (QoR-15) Score
Prazo: Baseline (preoperatively, before regional anesthesia) and 24 hours after surgery

The quality of postoperative recovery will be assessed using the Quality of Recovery-15 (QoR-15) questionnaire. The QoR-15 score ranges from 0 to 150, with higher scores indicating better quality of recovery. The primary analysis will compare the change in QoR-15 score from baseline to 24 hours postoperatively between the experimental and active comparator groups. An 8-point difference between groups is considered the minimal clinically important difference.

Baseline (preoperatively, before regional anesthesia) and 24 hours after surgery

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Postoperative Pain
Prazo: 6, 24, and 48 hours after surgery

Pain intensity will be assessed using the Numeric Rating Scale (NRS), both at rest and during mobilization. The NRS ranges from 0 (no pain) to 10 (worst pain imaginable).

6, 24, and 48 hours after surgery
Postoperative Opioid Consumption
Prazo: 24 and 48 hours after surgery

Total opioid consumption will be recorded and converted to oral morphine equivalents (OME).

24 and 48 hours after surgery
Postoperative Nausea and Vomiting
Prazo: 24 and 48 hours after surgery

The incidence of postoperative nausea and vomiting (PONV) will be recorded.

24 and 48 hours after surgery
Time to ambulation
Prazo: Day 0 (postoperative)

Time from completion of surgery to first postoperative ambulation will be recorded.

Day 0 (postoperative)
Postoperative Thigh Edema
Prazo: Day 0 and Day 1 after surgery

Postoperative changes in thigh circumference will be measured at three standardized locations: 15 cm above the superior pole of the patella, at the level of the patellar apex, and 10 cm below the patellar apex.

Day 0 and Day 1 after surgery
Postoperative Neuromuscular Recovery of the Thigh
Prazo: Day 0 and Day 1 after surgery

Neuromuscular recovery will be assessed using the Medical Research Council (MRC) scale, ranging from 0 (no muscle contraction) to 5 (normal muscle strength), across four motor tests: isometric heel press into the mattress, flattening of the popliteal fossa against the mattress, sliding knee flexion/extension, and straight-leg raise at 30 degrees.

Day 0 and Day 1 after surgery
Adverse Events Related to Regional Anesthesia
Prazo: Day 0

Adverse events related to locoregional anesthesia will be recorded, including signs of local anesthetic systemic toxicity (LAST) and persistent paresthesia.

Day 0
Patient Satisfaction With Analgesic Management
Prazo: 1 month after surgery

Patient satisfaction with postoperative analgesic management will be assessed using a 5-point Likert scale ranging from 1 (Very dissatisfied) to 5 (Very satisfied). Higher scores indicate greater patient satisfaction and a better outcome.

1 month after surgery

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Yoann ELMALEH, Hôpital Privé Claude Galien

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

15 de novembro de 2026

Conclusão Primária (Estimado)

15 de novembro de 2027

Conclusão do estudo (Estimado)

15 de novembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

30 de outubro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

30 de outubro de 2026

Primeira postagem (Real)

5 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

12 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

6 de novembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • COS-RGDS-2025-12-028-P-ELMALEH
  • 2026-A01040-51 (Outro identificador: ID-RCB)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .